Analysis of apoB Concentrations Across Early Adulthood and Predictors for Rates of Change Using CARDIA Study Data.


Journal

Journal of lipid research
ISSN: 1539-7262
Titre abrégé: J Lipid Res
Pays: United States
ID NLM: 0376606

Informations de publication

Date de publication:
12 2022
Historique:
received: 10 06 2022
revised: 14 09 2022
accepted: 03 10 2022
pubmed: 23 10 2022
medline: 27 12 2022
entrez: 22 10 2022
Statut: ppublish

Résumé

The cumulative exposure to apolipoprotein B (apoB)-containing lipoproteins in the blood during early adult life is a central determinant of atherosclerotic cardiovascular disease risk. To date, the patterns and rates of change in apoB through early adult life have not been described. Here, we used NMR to measure apoB concentrations in up to 3055 Coronary Artery Risk Development in Young Adults (CARDIA) Study participants who attended the years 2 (Y2), 7 (Y7), 15 (Y15), 20 (Y20), and 30 (Y30) exams. We examined individual-level spaghetti plots of apoB change, and we calculated average annualized rate of apoB concentration change during follow-up. We used multivariable linear regression models to assess the associations between CARDIA participant characteristics and annualized rates of apoB change. Male sex, higher measures of adiposity, lower HDL-C, lower Healthy Eating Index, and higher blood pressures were observed more commonly in individuals with higher apoB level at Y2 and Y20. Inter- and intra-individual variation in apoB concentration over time was substantial-while the mean (SD) rate of change was 0.52 (1.0) mg/dl/year, the range of annualized rates of change was -6.26 to +9.21 mg/dl/year. At baseline, lower first apoB measurement, female sex, White race, lower BMI, and current tobacco use were associated with apoB increase. We conclude that the significant variance in apoB level over time and the modest association between baseline measures and rates of apoB change suggest that the ability to predict an individual's future apoB serum concentrations, and thus their cumulative apoB exposure, after a one-time assessment in young adulthood is low.

Identifiants

pubmed: 36272600
pii: S0022-2275(22)00132-8
doi: 10.1016/j.jlr.2022.100299
pmc: PMC9694068
pii:
doi:

Substances chimiques

Apolipoproteins B 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

100299

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268201800006I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800005I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800007I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800004I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800003I
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146844
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest Dr Wilkins reports consulting work for 3M.

Auteurs

John T Wilkins (JT)

Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Electronic address: j-wilkins@northwestern.edu.

Hongyan Ning (H)

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Allan Sniderman (A)

Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

Neil Stone (N)

Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

James Otvos (J)

NMR Diagnostics, Laboratory Corporation of America Holdings (LabCorp), Morrisville, North Carolina, USA.

David R Jacobs (DR)

Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, USA.

Ravi Shah (R)

Department of Medicine, Division of Cardiology, Vanderbilt University School of Medicine Nashville, Tennessee, USA.

Venkatesh L Murthy (VL)

Department of Medicine and Radiology, University of Michigan, Ann Arbor, Michigan, USA.

Jamal Rana (J)

Department of Cardiology, Kaiser Permanente Oakland Medical Center, California, USA.

Norrina Allen (N)

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Donald M Lloyd-Jones (DM)

Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH